Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) announced its quarterly earnings results on Tuesday. The specialty pharmaceutical company reported ($0.05) earnings per share for the quarter, Bloomberg Earnings reports. Cumberland Pharmaceuticals had a negative net margin of 19.57% and a negative return on equity of 0.13%.

Shares of Cumberland Pharmaceuticals (NASDAQ CPIX) traded down $0.01 during mid-day trading on Tuesday, reaching $7.40. The company had a trading volume of 13,335 shares, compared to its average volume of 12,942. The company has a debt-to-equity ratio of 0.10, a current ratio of 4.88 and a quick ratio of 4.45. Cumberland Pharmaceuticals has a 52 week low of $4.93 and a 52 week high of $7.90.

TRADEMARK VIOLATION WARNING: “Cumberland Pharmaceuticals Inc. (CPIX) Releases Earnings Results” was first published by Watch List News and is the sole property of of Watch List News. If you are viewing this article on another website, it was illegally copied and reposted in violation of US & international copyright and trademark law. The original version of this article can be accessed at https://www.watchlistnews.com/cumberland-pharmaceuticals-inc-cpix-releases-earnings-results/1686514.html.

Cumberland Pharmaceuticals Company Profile

Cumberland Pharmaceuticals Inc (Cumberland) is a specialty pharmaceutical company. The Company is focused on the acquisition, development and commercialization of branded prescription products. The Company operates through specialty pharmaceutical products segment. The Company’s product portfolio includes Acetadote (acetylcysteine) Injection for the treatment of acetaminophen poisoning; Caldolor (ibuprofen) Injection for the treatment of pain and fever; Kristalose (lactulose) for Oral Solution for the treatment of chronic and acute constipation; Omeclamox-Pak, (omeprazole, clarithromycin, amoxicillin) for the treatment of Helicobacter pylori (H.

Earnings History for Cumberland Pharmaceuticals (NASDAQ:CPIX)

Receive News & Ratings for Cumberland Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cumberland Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.